to view your mail
U.S. Markets closed
Bayer Aktiengesellschaft (BAYZF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 3:36PM EST
372 reactions on $BAYZF conversation
Sign in to post a message.
People will regret not buying at these levels. The Monsanto episode is a tiny blip on the Bayry screen.
Finally, I added shares here. I am looking into it for atleast 5 years. I wish dividends are quarterly .
I have invested in this company without doing any research since it seamed it would put themselves together after the roundup settlement but now I am not sure. I would really like some others to share their thoughts about this company.
Almost behaving like a oil major..
As the cashflows seem unaffected and they have a decent approach on RNA treatment, it seems quite futureproof.
I might look to initiate a first position.
I have loaded up big time at this price! The enterprise value to ebitda stands at 5.7x only, and equity value as upside of 50% plus within 12 months with cushion of nearly 6% dividend yield while waiting. Bad news priced in already, and as cost reductions flow thru, cashflow will continue to climb. Despite the disastrous Monsanto acquisition, all current assets deserve a valuation multiple of 8x.....thereby implying equity valuation would double from here within 2 years.
Morgan Stanley reiterates but rating with Euro 68 as price target !!!!
Decade low price and double bottom being tested. If they announce more settlements (which are imminent), should result in 10% rise by November 10th. Pretty much most weak hands have been taken out. It is darkest before dawn ........! Today’s news about French loss is a yawner except for headline risk.....exposure is of $1mm and there is minimal risk of class action like in the U.S. When there appears to be no catalyst for rise, always something sticks ......this stock is trading at half the valuation of steel stocks (pessimism is extreme), and litigation charges are already baked in !
Bayer Fails to Settle U.S. Roundup Lawsuits, Risking Restart of Federal Trials
By Joel Rosenblatt | November 3, 2020
I see a huge fall today everywhere and Bayer is no exception. I think it will go eventually as low as 30 p/share. They should change asp they’re ceo
They are still world market leader in crop sciences. The corona effect causes lower prices but in the long term prices should raise again due to growing world population. Plus they have a strong pharma business.Bayer is valued as it would go bankrupt soon, but they still make billions of profit every year, although next year's profit has been cut by 15 %. I added at 44,50 #$%$and will buy more if it drops lower.
Everyone knows this vaccine is a piece of cake for Bayer, but because of the Monsanto scandal they have to lay low. Their trillion dollar punishment..
Good news is that according to “legal experts”, given company’s recent settlement of most contentious lawsuits with attorneys who had previously gone to trials, the odds of legal settlement with remaining lawsuits is very good. I can thus see this huge overhang disappearing soon, resulting in a much greater confidence for company’s future.
Is Bayer the big short? I bought heavily at #$%$54. It seems lost this year. I will wait until March ex dividend.
why is Bayer an OTC stock?
I don’t recall this stock ever going up. Lol
going down to 6 or 7. sorry
Bayer is still in rough times; The round-up issue was much bigger than expected and a lot of German investors will have that from the table first. The Agricultural division is weak, due to lower as expected performance in South America ( Brasil); the bottom seems to be #$%$ 38,- but be carefull the stock is vulnerable and weak. Seems to be a good time to enter now; buying between #$%$ 38-43; than sit and wait ( this is definitely long term stock); maybe in a few years the stock can reach 50-55 again, after the big re-organisations and finalizing the Round-Up affair.
Target Set by Barclays Buy EUR 75
Target Set by Sanford Bernstein Buy EUR 83.41
Target Set by Barclays Capital Buy EUR 75
"The time has come for Monsanto to end its baseless appeals and pay Mr. Johnson the money it owes him.” Today California Supreme Court refused to review Monsanto's trial loss to Lee Johnson. Statement from Lee's lawyers:
“The Miller Firm is pleased that the California Supreme Court denied Monsanto's latest attempt to skirt responsibility for the significant harm it caused Mr. Johnson. Multiple judges have now affirmed the jury’s unanimous finding that Monsanto maliciously concealed Roundup's cancer risk and caused Mr. Johnson to develop a deadly form of cancer. The time has come for Monsanto to end its baseless appeals and pay Mr. Johnson the money it owes him.”
in at 12.2, but took a small position waiting for it to pop....still thinking about another position at low 14.
A Successful U.S. Missile Intercept Ends the Era of Nuclear Stability
How capital market firms are adjusting business plans due to COVID-19
Yahoo Finance Video
Will you get a new $1,200 stimulus check during December?
Advertise With Us
© 2020 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research